These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26684534)

  • 1. Sugammadex - time of onset: nine months.
    Dalton J; Van Hasselt G
    Anaesthesia; 2016 Jan; 71(1):115-6. PubMed ID: 26684534
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex.
    Ploeger BA; Smeets J; Strougo A; Drenth HJ; Ruigt G; Houwing N; Danhof M
    Anesthesiology; 2009 Jan; 110(1):95-105. PubMed ID: 19104176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugammadex--a short review and clinical recommendations for the cardiac anesthesiologist.
    Hemmerling TM; Zaouter C; Geldner G; Nauheimer D
    Ann Card Anaesth; 2010; 13(3):206-16. PubMed ID: 20826961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo animal studies with sugammadex.
    Booij LH; van Egmond J; Driessen JJ; de Boer HD
    Anaesthesia; 2009 Mar; 64 Suppl 1():38-44. PubMed ID: 19222430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of magnesium sulphate on sugammadex reversal time for neuromuscular blockade: a randomised controlled study.
    Germano Filho PA; Cavalcanti IL; Barrucand L; Verçosa N
    Anaesthesia; 2015 Aug; 70(8):956-61. PubMed ID: 25829048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sugammadex--a new agent for reversal of neuromuscular blockade].
    Claudius C; Gätke MR
    Ugeskr Laeger; 2009 Mar; 171(13):1091. PubMed ID: 19321086
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical pharmacology of sugammadex.
    Bom A; Hope F; Rutherford S; Thomson K
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
    Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H
    Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
    Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
    Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A train-of-four ratio of 0.9 may not certify adequate recovery after sugammadex.
    Suzuki T
    Acta Anaesthesiol Scand; 2011 Mar; 55(3):368-9. PubMed ID: 21288221
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergency use of sugammadex after failure of standard reversal drugs.
    Lenz A; Hill G; White PF
    Anesth Analg; 2007 Mar; 104(3):585-6. PubMed ID: 17312213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
    Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
    Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugammadex: a novel approach to reversal of neuromuscular blockade.
    Aniskevich S; Leone BJ; Brull SJ
    Expert Rev Neurother; 2011 Feb; 11(2):185-98. PubMed ID: 21306205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sugammadex in clinical practice.
    Mirakhur RK
    Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics.
    Sparr HJ; Vermeyen KM; Beaufort AM; Rietbergen H; Proost JH; Saldien V; Velik-Salchner C; Wierda JM
    Anesthesiology; 2007 May; 106(5):935-43. PubMed ID: 17457124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugammadex: a novel neuromuscular blocker binding agent.
    Fields AM; Vadivelu N
    Curr Opin Anaesthesiol; 2007 Aug; 20(4):307-10. PubMed ID: 17620836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sugammadex in anesthesia practice.
    Duvaldestin P; Plaud B
    Expert Opin Pharmacother; 2010 Nov; 11(16):2759-71. PubMed ID: 20977408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclodextrins and the emergence of sugammadex.
    Booij LH
    Anaesthesia; 2009 Mar; 64 Suppl 1():31-7. PubMed ID: 19222429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.